| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Stroke: Competing Treatments and Market Entry Considerations
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Global |
Published |
1 June 2010 |
Number of Pages |
140 |
1-3 hours, 24 hour max |
|
Publisher |
Biopharm Reports |
File Format |
- |
This report presents the findings of a global clinical survey on competing treatments for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 clinics worldwide, which provided detailed information of their treatment practices. This survey was carried out to evaluate competing therapies and market entry factors, relating to the treatment of Stroke.
In 2008, the World Stroke Congress reported that 20 million Stroke events occur globally each year and account for 5.7 million deaths. Stroke is now the second most common cause of death worldwide and a major cause of disability. The incidence of Stroke is expected to increase by 30% over the next decade (6th World Stroke Congress, Vienna, Austria, 24th-27th September 2008).
In a field where therapies are often unsatisfactory, physicians seek to extend their understanding and use of available treatments to improve patient outcomes. Knowledge in these areas is also important to drug developers, who seek a better understanding of prescribing practices and treatment needs and limitations from the clinician's perspective, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted a global survey on current treatments and drug prescribing practices for Stroke. This survey involved the participation of more than 230 clinical centres in 41 countries.
Overview:
Global quantitative data on treatments and drug prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), provided by more than 230 clinics in 41 countries.
More than 98% of study participants are practicing physicians, working in areas of Stroke treatment. Of these, 65% are specialists in Stroke treatment. Leading participant countries were USA, Italy, India, Canada, Japan, Germany, Spain, Belgium and China.
More than 60% of the clinical centres participating in this study were hospital specialist Stroke units, specialist Stroke practices or private Stroke clinics.
Detailed information on drugs classes used in the treatment of patients with Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA), together with population-based drug prescribing profiles.
Quantitative prescribing data on specific antiplatelet, anticoagulant, thrombolytic and other drugs used in the treatment of Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA).
The percentage of Ischaemic Stroke patients prescribed the antiplatelets aspirin (e.g. Aspro®), dipyridamole (e.g. Persantine®), clopidogrel (e.g. Plavix®), aspirin/dipyridamol (e.g. Asasantin®), ticlopidine (e.g. Ticlid®) and others (specified).
The percentage of Ischaemic Stroke patients prescribed the coagulants warfarin (e.g. Coumadin®), heparin (e.g. Hepalean®), dicoumarol (e.g. Dicoumarol), antithrombin III (e.g. Thrombate III®), argatroban (e.g. Novastan®), bivalirudin (e.g. Angiomax®), sandoparin (e.g. Certoparin®), enoxaparin (e.g. Lovenox®), ethyl biscoumacetate (e.g. Tromexan®), nadroparin (e.g. Fraxiparine®) or others (specified)
The percentage of Ischaemic Stroke patients prescribed the thrombolytic drug Tissue Plasminogen Activator (e.g. Alteplase®) or others (specified).
The percentage of Haemorrhagic Stroke patients prescribed clotting factor (e.g. vitamin K), clotting proteins (e.g. prothrombin), calcium channel blockers (e.g. nimodipine), antihypertensives, platelets, plasma or other (specified).
Prescribing practices on the use of specific drug combinations, used in the treatment of Ischaemic and Haemorrhagic Stroke.
The percentage of Haemorrhagic Stroke patients treated surgically by aneurysm clipping, endovascular treatment of aneurysms, surgical arteriovenous malformation (AVM) removal, steriotactic radiosurgery, endovascular treatment of AVMs, removal of haematoma, ventriculostomy, carotid endarterectomy, craniotomy and others (specified).
From the clinician's perspective: current limitations in the diagnosis and treatment of Stroke.
Visitor Comments
|
All posts are pre-moderated and must obey the house rules. |
|
Healthcare and Medical Company Profiles
Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.
Competitor Tracking
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
US herbal products market grew by 3% through 2012
US digestive remedies market to benefit from an unexpected surge in cases of norovirus
US ear care market led by Debrox with a 40% value share
Digital pathology market to reach a value of $542 million by 2018
Infectious disease treatments market driven by growth in middle-income to low-income countries
